welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Study of Ataluren in >=2 to <5 Year-Old Males With Duchenne Muscular Dystrophy
study id #: NCT02819557
condition: Duchenne Muscular Dystrophy
This is a Phase 2, multiple-dose, open-label study evaluating the safety, and pharmacokinetics (PK) of ataluren in patients aged >=2 to <5 years old with Duchenne muscular dystrophy caused by a nonsense mutation in the dystrophin gene. The study includes a 4-week screening period, a 4-week study period, and a 48-week extension period for patients who complete the 4-week study period (52 weeks total treatment).
mechanism of action: Stop codon read through to promote dystrophin production
last updated: July 08, 2019
start date: June 16, 2016
estimated completion: February 9, 2018
phase of development: Phase 2
size / enrollment: 14
This protocol describes a Phase 2, multiple-dose, open-label study evaluating the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ataluren in patients aged >=2 to <5 years old with nmDMD. In nmDMD, early start of treatment is important and necessary and, therefore, it is relevant to understand the correct and tolerable dose in this age group, particularly since ataluren is dosed by weight. The study will include a 4-week screening period, a 4-week study period, and a 48-week extension period for patients who complete the 4-week study period (52 weeks total treatment). The objective of the extension period is to assess the long-term safety of chronic administration of ataluren in this patient population.
- Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment [Time Frame: 56 weeks]
Safety of ataluren as measured by type, frequency, severity, timing, and relationship to study drug of treatment emergent adverse events,laboratory abnormalities and electrocardiograms
- Maximum Plasma Concentration [Cmax] [Time Frame: 4 weeks]
Pharmacokinetic parameters (tmax, Cmax) based on frequent blood sampling for PK (drug concentrations) on Days 1 and 28 of ataluren treatment.
- Area Under the Curve [AUC] and Cmin [Time Frame: 4 weeks]
Pharmacokinetic parameters C(trough) @ 6hrs, and AUC (0-t), t=last time point) based on frequent blood sampling for PK (drug concentrations) on Days 1 and 28 of ataluren treatment.
- Descriptive assessments of efficacy [Time Frame: 56 weeks]
TFTs (time to walk/run 10 meters, time to climb 4 stairs, time to descend 4 stairs, and time to stand up from a supine position) ∙ NSAA ∙ Bayley-III (in patients <=30 months old)
- Effects on growth parameters [Time Frame: 56 weeks]
Changes in body weight, height, and BMI
• Males >=2 to <5 years of age
• Body weight >=12 kg
• Diagnosis of DMD
• Nonsense mutation in at least 1 allele of the dystrophin gene
• Participation in any other drug or device clinical investigation
• Ongoing use of prohibited concomitant medications
Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)The objective of this study is to assess...
Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular DystrophyThis study is single arm, single center ...
Boy with muscular dystrophy writes heartfelt note to Scottish leaderMichael Young, 9, wrote a letter to Scot...
Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)The aim of this study is to provide cont...
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation DystrophinopathyThe primary objective of this study is t...
A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who H...This study is designed to generate addit...
Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular DystrophyThe primary objective of this study is t...
Design of a phase 3 trial to evaluate the long-term efficacy and safety of ataluren in patients with nonsense mutati...Ataluren is conditionally approved by th...
Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilo...Wave Life Sciences Ltd., a biotechnology...
Ataluren treatment of patients with nonsense mutation dystrophinopathyIntroduction: Dystrophinopathy is a ra...
One-Year Follow Up of Three Italian Patients With Duchenne Muscular Dystrophy Treated With Ataluren: Is Earlier Bett...Background: Ataluren was approved for t...